Philadelphia, PA (PRWEB) December 31, 2015
Morgan & Morgan filed the first complaint* against Janssen Pharmaceuticals for its alleged negligence and wrongful conduct in the patenting, marketing, and labeling of Invokana. Invokana, also known as canagliflozin, is a Type 2 diabetes drug that causes adverse reactions in diabetes patients.
In May, 2015, the FDA released new findings about the potential risks associated with Invokana and determined that the drug was dangerous for individuals with diabetes. Invokana was reported to cause ketoacidosis, a complication in which the patient produces too much acid in his or her blood. The drug has been available since 2013.
The lawsuit claims that Janssen knew about the increased risk of severe injury and yet continued to defend and profit off Invokana., misrepresenting the drug to both physicians and the public. The plaintiff allegedly developed diabetic ketoacidosis because of his use of Invokana and required prolonged hospitalization. The lawsuit seeks compensatory and punitive damages from the defendant.
According to the lawsuit, the company allegedly knew, or at least should have known, about the risks associated with Invokana as data from pre-clinical studies, animal testing, genetic models, and event reports all provided evidence that the drug was dangerous. Diabetic ketoacidosis can cause cerebral edema, pulmonary edema, myocardial infarction, and a variety of other life-threatening complications.
The lawsuit claims that the plaintiff will be burdened with further medical expenses regarding the complications suffered as a result of taking Invokana. The plaintiff will have to pay for physician care, monitoring, and treatment. The lawsuit states that these complications could have been avoided if the plaintiff had been aware of the risks associated with Invokana beforehand as he would have used another form of treatment.
For more information on the class action lawsuit against Janssen Pharmaceuticals, visit Morgan & Morgan’s Invokana class action webpage at http://www.forthepeople.com/class-action-lawyers/invokana-ketoacidosis-lawsuit/.
- Lopez Mchugh, LLP. et. al., v. Janssen Pharmaceuticals, Inc. et. al., case number 151200653, in the Court of Common Pleas, Philadelphia County, Pennsylvania, Civil Trial Division
For further press inquiries contact:
Dov Slansky – Attorney